Testing sintilimab, anlotinib, and chemo for pleural mesothelioma
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 study tests whether adding three medicines—sintilimab, anlotinib, and standard platinum chemo—can control malignant pleural mesothelioma that cannot be removed by surgery. It may help shrink tumors and slow disease progression, but you must meet specific health and prior-treatment requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and have malignant pleural mesothelioma that cannot be surgically removed or has spread.
- You have at least one measurable tumor spot on scans that doctors can track over time.
- You have not had prior whole-body (systemic) cancer treatment for advanced or metastatic disease (some limited past chemo/radiation may be allowed if timing fits).
- Your general strength is good (ECOG score 0–1) and doctors expect you to live more than 3 months.
- Your blood and organ tests must be adequate (enough white cells, platelets, hemoglobin, and acceptable liver/kidney and clotting results).
- You cannot have certain recent immune-blocking treatments, uncontrolled autoimmune disease, recent immune-suppressing steroids, major bleeding risks, or uncontrolled infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding more chemotherapy directly into the belly after surgery can improve outcomes for people with a specific type of peritoneal mesothelioma. It may help reduce the chance of the cancer coming back.
This trial tests a combination of four drugs (sintilimab, bevacizumab, pemetrexed, and cisplatin) to see if they can shrink or control peritoneal mesothelioma that cannot be surgically removed. It may be an option if you have this rare cancer and are in fairly good health.
This trial tests adding a drug called fianlimab to another drug (cemiplimab) plus chemotherapy for people with a type of lung cancer called pleural mesothelioma. It aims to see if the combination is more effective than cemiplimab plus chemo alone.
This trial studies how well pembrolizumab (an immune therapy) works when added to chemotherapy before image-guided surgery for malignant pleural mesothelioma. It aims to shrink or control the cancer and improve surgical results by combining treatments.
This trial tests a new combination of two immunotherapy drugs plus standard chemotherapy and a targeted therapy for people with advanced mesothelioma who have not had treatment before. The goal is to see if this combination can shrink tumors and help people live longer.
This trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemotherapy helps people with malignant mesothelioma live longer and feel better. It's for patients who can't have surgery or radiation, and it may be an option if you haven't had treatment before or have had limited prior treatment.
Hear when a new Mesothelioma, Malignant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.